188 related articles for article (PubMed ID: 32592066)
1. Lymphocyte activation gene-3 (LAG3) mRNA and protein expression on tumour infiltrating lymphocytes (TILs) in oesophageal adenocarcinoma.
Gebauer F; Krämer M; Bruns C; Schlößer HA; Thelen M; Lohneis P; Schröder W; Zander T; Alakus H; Buettner R; Loeser H; Quaas A
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2319-2327. PubMed ID: 32592066
[TBL] [Abstract][Full Text] [Related]
2. Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma.
Noble F; Mellows T; McCormick Matthews LH; Bateman AC; Harris S; Underwood TJ; Byrne JP; Bailey IS; Sharland DM; Kelly JJ; Primrose JN; Sahota SS; Bateman AR; Thomas GJ; Ottensmeier CH
Cancer Immunol Immunother; 2016 Jun; 65(6):651-62. PubMed ID: 27020682
[TBL] [Abstract][Full Text] [Related]
3. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR
J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868
[TBL] [Abstract][Full Text] [Related]
4. Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas.
Arolt C; Meyer M; Ruesseler V; Nachtsheim L; Wuerdemann N; Dreyer T; Gattenlöhner S; Wittekindt C; Buettner R; Quaas A; Klussmann JP
Cancer Immunol Immunother; 2020 Jul; 69(7):1363-1373. PubMed ID: 32232506
[TBL] [Abstract][Full Text] [Related]
5. Lymphocyte-activating gene-3 expression is associated with tumor-infiltrating lymphocyte levels in HER2-positive breast cancers.
Lee S; Kim JY; Lee SJ; Kwon SW; Jung HJ; Jung SJ; Kim KB; Choi KU; Lee CH; Huh GY; Kim A
Medicine (Baltimore); 2021 Dec; 100(50):e28057. PubMed ID: 34918659
[TBL] [Abstract][Full Text] [Related]
6. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
7. High CD8
Koemans WJ; van Dieren JM; van den Berg JG; Meijer GA; Snaebjornsson P; Chalabi M; Lecot F; Riedl R; Krijgsman O; Hofland I; Broeks A; Voncken FEM; Peppelenbosch MP; Sosef MN; van Sandick JW; Kodach LL
Histopathology; 2021 Aug; 79(2):238-251. PubMed ID: 33660299
[TBL] [Abstract][Full Text] [Related]
8. Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma.
Fröhlich A; Sirokay J; Fietz S; Vogt TJ; Dietrich J; Zarbl R; Florin M; Kuster P; Saavedra G; Valladolid SR; Hoffmann F; Flatz L; Ring SS; Golletz C; Pietsch T; Strieth S; Brossart P; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
EBioMedicine; 2020 Sep; 59():102962. PubMed ID: 32861198
[TBL] [Abstract][Full Text] [Related]
9. LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma.
Keane C; Law SC; Gould C; Birch S; Sabdia MB; Merida de Long L; Thillaiyampalam G; Abro E; Tobin JW; Tan X; Xu-Monette ZY; Young KH; Gifford G; Gabreilli S; Stevenson WS; Gill A; Talaulikar D; Jain S; Hernandez A; Halliday SJ; Bird R; Cross D; Hertzberg M; Gandhi MK
Blood Adv; 2020 Apr; 4(7):1367-1377. PubMed ID: 32267932
[TBL] [Abstract][Full Text] [Related]
10. LAG3 and TIGIT Expression on Tumor-Infiltrating Lymphocytes in Cutaneous Melanoma.
Naimy S; Bzorek M; Eriksen JO; Løvendorf MB; Litman T; Dyring-Andersen B; Gjerdrum LMR
Dermatology; 2024; 240(1):156-163. PubMed ID: 37952520
[TBL] [Abstract][Full Text] [Related]
11. An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.
Bottai G; Raschioni C; Losurdo A; Di Tommaso L; Tinterri C; Torrisi R; Reis-Filho JS; Roncalli M; Sotiriou C; Santoro A; Mantovani A; Loi S; Santarpia L
Breast Cancer Res; 2016 Dec; 18(1):121. PubMed ID: 27912781
[TBL] [Abstract][Full Text] [Related]
12. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8
Kim HD; Song GW; Park S; Jung MK; Kim MH; Kang HJ; Yoo C; Yi K; Kim KH; Eo S; Moon DB; Hong SM; Ju YS; Shin EC; Hwang S; Park SH
Gastroenterology; 2018 Dec; 155(6):1936-1950.e17. PubMed ID: 30145359
[TBL] [Abstract][Full Text] [Related]
13. CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer.
Lee SJ; Jun SY; Lee IH; Kang BW; Park SY; Kim HJ; Park JS; Choi GS; Yoon G; Kim JG
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1005-1014. PubMed ID: 29520442
[TBL] [Abstract][Full Text] [Related]
14. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.
Mishra AK; Kadoishi T; Wang X; Driver E; Chen Z; Wang XJ; Wang JH
Oncotarget; 2016 Dec; 7(49):81341-81356. PubMed ID: 27835902
[TBL] [Abstract][Full Text] [Related]
15. Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma.
Han S; Zhang C; Li Q; Dong J; Liu Y; Huang Y; Jiang T; Wu A
Br J Cancer; 2014 May; 110(10):2560-8. PubMed ID: 24691423
[TBL] [Abstract][Full Text] [Related]
16. Indoleamine 2,3-Dioxygenase (IDO) Expression Is an Independent Prognostic Marker in Esophageal Adenocarcinoma.
Loeser H; Kraemer M; Gebauer F; Bruns C; Schröder W; Zander T; Alakus H; Hoelscher A; Buettner R; Lohneis P; Quaas A
J Immunol Res; 2020; 2020():2862647. PubMed ID: 33029538
[TBL] [Abstract][Full Text] [Related]
17. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
18. The co-expression characteristics of LAG3 and PD-1 on the T cells of patients with breast cancer reveal a new therapeutic strategy.
Du H; Yi Z; Wang L; Li Z; Niu B; Ren G
Int Immunopharmacol; 2020 Jan; 78():106113. PubMed ID: 31841754
[TBL] [Abstract][Full Text] [Related]
19. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma.
Fukunaga A; Miyamoto M; Cho Y; Murakami S; Kawarada Y; Oshikiri T; Kato K; Kurokawa T; Suzuoki M; Nakakubo Y; Hiraoka K; Itoh T; Morikawa T; Okushiba S; Kondo S; Katoh H
Pancreas; 2004 Jan; 28(1):e26-31. PubMed ID: 14707745
[TBL] [Abstract][Full Text] [Related]
20. Lymphocyte-activated gene-3 (LAG3) protein expressed in tumor-infiltrating lymphocytes of colorectal cancer.
Xu J; Shen D; Zhang T; Wang J; De W; Zhang J
Pol J Pathol; 2021; 72(4):324-330. PubMed ID: 35308003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
